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Summary
Objective: Proinﬂammatory cytokine-induced expression of matrix metalloproteinases (MMPs) is a major cause of arthritic cartilage destruc-
tion. The neuropeptide, a-melanocyte-stimulating hormone (a-MSH), has been detected in the synovial ﬂuid of arthritis patients, where it is
thought to play an anti-inﬂammatory role. Here, we examined whether a-MSH acts via downregulation of MMP expression, and sought to
elucidate the intracellular signal pathways underlying this effect.
Design: Human chondrosarcoma cell line, HTB-94 (SW1353) was pretreated with or without a-MSH and then treated with tumor necrosis
factor-a (TNF-a). The effect of a-MSH on TNF-a-induced MMP-13 expression and mitogen-activated protein kinases’ (MAPKs) activation
were determined by reverse transcriptase-polymerase chain reaction and Western blot analysis. Additionally, the intracellular signaling of
a-MSH was investigated using the inhibitors of MAPK and nuclear factor kB (NF-kB) and plasmids encoding dominant negative (dn) forms
of inhibitor kB kinase-a (IKKa) and inhibitor kB kinase-b (IKKb).
Results: We found that a-MSH pretreatment inhibited TNF-a-induced MMP-13 expression and p38 kinase phosphorylation in HTB-94 human
chondrosarcoma cells. TNF-a-induced MMP-13 expression was not suppressed by extracellular signal-regulated kinase (ERK) inhibitors
(PD98059 and U0126) or a c-jun terminal kinase (JNK) inhibitor (SP600125), but was inhibited by inhibitors of p38 kinase (SB203580)
and NF-kB (SN-50 peptide) and dnIKKa and dnIKKb.
Conclusions: Our results suggest that a-MSH regulates TNF-a-induced MMP-13 expression by decreasing p38 kinase phosphorylation and
subsequent NF-kB activation in human chondrocytes and may be an effective inhibitor of MMP-13-mediated collagen degradation, providing
new potential opportunities for the development of anti-arthritis therapeutics.
ª 2007 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Thea-melanocyte-stimulating hormone (a-MSH), a 13amino
acid neuropeptide produced by intracellular cleavage of the
proopiomelanocortin (POMC) hormone, mediates commu-
nication between the nervous and immune systems1. In
addition, a-MSH has been demonstrated to have anti-
inﬂammatory activity in various disease models, including
arthritis, septic shock induced by hepatic injury, and endotox-
emia/ischemia2e4, suggesting that a-MSH may be a promis-
ing candidate therapeutic drug for inﬂammatory diseases.
The anti-inﬂammatory activity ofa-MSHhas been associated1Source of support: This work was supported by the Molecular
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115with reduction of proinﬂammatory cytokines, suchas interleu-
kin-1b (IL-1b), interleukin-6 (IL-6), interleukin-8 (IL-8), inter-
feron-g (IFN-g) and tumor necrosis factor-a (TNF-a)2e5,
and inhibition of proinﬂammatory signaling events, such as
activation of nuclear factor kB (NF-kB)6. Mechanistically,
a-MSH has been shown to exert its cellular effects by binding
to ﬁve different G protein-coupled receptors called melano-
cortin receptors (MC1R through MC5R)
7. MC1R, which is
expressed on the surface of leukocytes, is thought to be
the major receptor mediating the anti-inﬂammatory activity
of a-MSH8. Higher a-MSH concentration observed in syno-
vial ﬂuid of the arthritis patients was correlated with the lower
level of inﬂammation4. In animal model studies, it was also
suggested that a-MSH may be beneﬁcial for the treatment
of arthritis9,10.
Proteolytic degradation of the articular cartilage matrix is
a hallmark of joint inﬂammation such as osteoarthritis (OA)
and rheumatoid arthritis (RA). Excess matrix metalloprotei-
nase (MMP) production has been associated with the
pathology of many diseases, including tumor invasion/
metastasis and arthritic disease and play a major role in
the degradation of type II collagen11e13. The pathology of
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ﬂammatory cytokines including IL-1b, IL-6, transforming
growth factor-b (TGF-b), and TNF-a14. Inﬂammatory cyto-
kines such as TNF-a and IL-1b have been shown to induce
expression of MMP-1, MMP-3, MMP-8, MMP-9, and
MMP-1315 and subsequent degradation of both collagen
and proteoglycans16e20. A subgroup of MMPs, known as
collagenase (MMP-1, MMP-8, and MMP-13) is the most
effective enzymes that can initiate cleavage on native
MMPs17. Previous studies demonstrate that MMP-13
(collagenase-3) localized in articular cartilage is a key medi-
ator of cartilage degradation15,21e24 and elevated in joint
disorders25,26, suggesting that MMP-13 may play a major
role in the destruction of cartilage which is made of type II
collagen and proteoglycans. Proinﬂammatory cytokine-
induced MMP-13 expression in human chondrocytes and
animal models of arthritis has been shown to be regulated
by activation of mitogen-activated protein kinases (MAPKs),
most notably p38 kinase and several transcription factors,
including activating protein-1 (AP-1) and NF-kB27e31.
We recently reported that a-MSH downregulates TNF-a
production by inhibiting p38 kinase phosphorylation and
subsequent NF-kB activation in leukocytes32. However, al-
though a-MSH has been localized to inﬂammatory sites in
patients with different kinds of arthritides4, no previous
study has sought to elucidate the precise molecular mech-
anism(s) underlying the anti-arthritis effects of a-MSH. In
the present study, we investigated the effects of a-MSH
on TNF-a-induced MMP-13 expression in the chondrosar-
coma cell line, HTB-94 (SW1353) which behaves similarly
to primary chondrocytes in terms of inﬂammatory cyto-
kine-induced MMP expression27. We found that a-MSH in-
hibits TNF-a-induced MMP-13 expression in HTB-94 cells
by inhibiting TNF-a-induced p38 kinase activation and the
downstream activation of NF-kB. To our knowledge, this
is the ﬁrst report showing that a-MSH inhibits the production
of MMP-13, a major player in arthritic cartilage degradation.MethodsMATERIALSThe goat anti-MC1R polyclonal antibody was obtained
from Research Diagnostic Inc. (Flanders, NJ). The rabbit
anti-phospho-p38 kinase polyclonal antibody, mouse anti-
phospho-extracellular-signal regulated kinase 1/2 (ERK1/2)
monoclonal antibody, rabbit anti-phospho-stress-activated
protein kinase/c-jun terminal kinase (SAPK/JNK) polyclonal
antibody, rabbit anti-phospho-inhibitor of kappaB (IkB)-a
polyclonal antibody, rabbit anti-phospho-inhibitor kB kinase
(IKK) a/b polyclonal antibody, anti-mouse and anti-rabbit
IgG horseradish peroxidase (HRP)-conjugated antibody
were purchased from Cell Signaling Technology (Beverly,
MA). The p38 kinase inhibitor (SB203580), the ERK1/2
inhibitors (PD98059 and U0126), and the JNK inhibitor
(SP600125) were purchased from Calbiochem (La Jolla,
CA). The ﬂuorescein isothiocyanate (FITC)-conjugated rab-
bit anti-goat polyclonal antibody was purchased from Sigma
(St. Louis, MO). The mouse anti-MMP-1 and MMP-13
monoclonal antibodies were purchased from Oncogene
(San Diego, CA). The mouse anti-MMP-3 antibody was
purchased from Chemicon (Temecula, CA). The mouse
anti-MMP-9 antibody was purchased from Santa Cruz
Biotechnology (Santa Cruz, CA). The recombinant human
TNF-a was purchased from BD Bioscience (Franklin Lakes,
NJ), and the human active Fluorokine E (MMP-13ﬂuorescent assay kit) was purchased from R&D Sys-
tem (Minneapolis, MN). The a-MSH antagonist, growth
hormone-releasing hexapeptide-6 (GHRP-6)was purchased
from Bachem (Bubendrof, Switzerland).CELL CULTURETheHTB-94 human chondrosarcoma cell linewas cultured
in Dulbecco’s modiﬁed Eagle’s medium (DMEM, Hyclone,
Logan) supplemented with 100 units/ml penicillin and
100 mg/ml streptomycin containing 10% heat-inactivated
fetal bovine serum (FBS) (Hyclone, Logan). Cells were se-
rum-starved for 24 h (DMEM containing 1% FBS) before
stimulation and/or other treatment. After serum starvation,
cells were treated with each kinase inhibitors (PD98059,
U0126, SB203580, and SP600125, 10 mM each), NF-kB
inhibitor (50 nM), and a-MSH (200 nM) and then treated
with TNF-a (50 ng/ml) for 24 h. Human OA cartilage was
obtained from 64-year-old female patient undergoing arthro-
plasty for the OA knee joints. Transfer of material was ap-
proved by the appropriate Human Subjects Committees.
The sample satisﬁed the AmericanCollege of Rheumatology
classiﬁcation criteria forOAof the knee cartilage tissueswere
sampled down to the subchondral bone from tibial plateau of
each specimen within 60 min of operation.REVERSE TRANSCRIPTASE-POLYMERASE
CHAIN REACTION (RT-PCR)Total RNA was isolated using the TRIzol reagent (Invitro-
gen, Carlsbad), according to the manufacturer’s instruc-
tions. The reverse transcription of RNA to cDNA was
performed with the SuperScript IIþ reverse transcriptase (In-
vitrogen). The PCR primers and conditions were as follows.
For the MCRs, the primers were MC1R, forward 5
0-CTT
CTT CCT GGC TAT GCT GG-30, reverse 50-TCA CCA
GGA GCA TGT CAG CA-30; MC3R, forward 50-GCG ACT
ACC TGA CCT TCG AG-30, reverse 50-CAT GCA TGA
GTG TTG CTG TG-30; MC4R, forward 50-TGC AGC CTG
CTT TCA ATT GC-30, reverse 50-GAT TCT GAG GAC
AAG AGA TG-30; and MC5R, forward 50-GAT AGC AGA
CGC CTT GTG-30, reverse 50-TTC TGA GGG CAA GAA
AGC AT-30; and the ampliﬁcation conditions were 30 cycles
of 94C for 45 s, 56C for 45 s and 72C for 45 s. For hu-
man type II collagen, the primers were 50-ATG ACA ATC
TGG CTC CCA AC-30 (forward) and 50-GCC CTA TGT
CCA CAC CGA ATT-30 (reverse) and the ampliﬁcation con-
ditions were 28 cycles of 94C for 1 min, 60C for 1 min and
72C for 1 min. For MMP-1, the primers were 50-CTG AAG
GTG ATG AAG CAG CC-30 (forward) and 50-AGT CCA
AGA GAA TGG CCG AG-30 (reverse) and the ampliﬁcation
conditions were 30 cycles of 94C for 1 min, 56C for 1 min
and 72C for 1 min. For MMP-3, the primers were 50-CCT
CTG ATG GCC CAG AAT TGA-30 (forward) and 50-GAA
ATT GGC CAC TCC CTG GGT-30 (reverse) and the ampli-
ﬁcation conditions were 30 cycles of 94C for 1 min, 58C
for 1 min and 72C for 1 min. For MMP-8, the primers
were 50-ATG GAC CAA CAC CTC CGC AA-30 (forward)
and 50-GTC AAT TGC TTG GAC GCT GC-30 (reverse)
and the ampliﬁcation conditions were 30 cycles of 94C
for 1 min, 60C for 1 min and 72C for 1 min. For MMP-9,
the primers were 50-CGC AGA CAT CGT CAT CCA GT-30
(forward) and 50-GGA TTG GCC TTG GAA GAT GA-30 (re-
verse) and the ampliﬁcation conditions were 30 cycles of
94C for 1 min, 62C for 2 min and 72C for 3 min. For
MMP-13, the primers were 50-GAC TTC ACG ATG GCA
TTG CTG-30 (forward) and 50-GCA TCA ACC TGC TGA
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were 30 cycles of 94C for 1 min, 60C for 2 min and
72C for 3 min. For human b-actin (positive control), the
primers were 50-ATG TTT GAG ACC TTC AAC AC-30
(forward) and 50-CAG GTC ACA CTT CAT GAT GC-30
(reverse) and the ampliﬁcation conditions were 30 cycles
of 94C for 45 s, 56C for 45 s and 72C for 45 s27,32e34.
PCR products were resolved on 1.5% agarose gels and
visualized by staining with ethidium bromide (EtBr) and UV
transillumination.WESTERN BLOT ANALYSISCells were lysed in a buffer containing 1% NP-40, 0.5%
sodium deoxycholate, 1% sodium dodecyl sulfate (SDS),
1 mM ethylenediaminetetraacetic acid (EDTA), 1 mM
ethylene glycol-bis(2-aminoethylether)-N,N,N0,N0-tetraacetic
acid (EGTA), 1 mM sodium orthovanadate, 1 mM leupeptin,
and 1 mM phenylmethylsulfonyl ﬂuoride (PMSF) in phos-
phate-buffered saline (PBS) (pH 7.4). Equivalent amounts
of protein (30 mg) were size-fractionated in a 12% SDS-poly-
acrylamide gel and then transferred onto a nitrocellulose
membrane. The membrane was blocked with 5% skim milk
in tris-buffered saline containing 0.05% Tween-20 (TBS-T)
and blotted with the appropriate antibodies. The blots were
developed using an HRP-conjugated secondary antibody
and visualized by chemiluminescence using an ECL kit
(Amersham Biosciences, Uppsala).IMMUNOFLUORESCENCE ANALYSISFor MC1R immunostaining, the antibody against the
N-terminal region of the human MC1R was used. Cells
were plated on coverslips (2 104 cells/coverslip) and treated
with TNF-a (50 ng/ml) for 30 min. Following treatment, the
cells were blocked with 2% bovine serum albumin (BSA)
in TBS-T (TBS containing 0.05% Tween-20) for 1 h at
room temperature, and then incubated with anti-MC1R (di-
luted 1:100 in blocking buffer) for 3 h at room temperature.
The slides were washed with TBS-T, incubated with the
FITC-conjugated secondary antibody (diluted 1:200) for
30 min at room temperature, and then washed and sealed
with a coverslip. The slides were viewed with an Axioskop
inverted ﬂuorescence microscope (Carl Zeiss, Gottingen).TRANSIENT TRANSFECTION OF DOMINANT
NEGATIVE (dn) DNACells were transiently transfected with plasmids encoding
the dn forms of IKKa, IKKb and NF-kB as previously
described35. Transfection was performed using the Lipofect-
amine 2000 reagent (Invitrogen), according to the manufac-
turer’s instructions. The transfected cells were cultured in
complete medium for 24 h, and then used as indicated in
each experiment.MMP-13 ACTIVITY ASSAYMMP-13 speciﬁc enzymatic activity is basedonaﬂuorimet-
ric assay. Anti-MMP-13 antibody pre-coated 96-well plate
was used for speciﬁcity and the assay was performed
according to the manufacturer’s instructions (Fluorokine E
kit; R&DSystems). Cells were plated in 24-well tissue culture
plates, pretreated with or without a-MSH (200 nM) for 24 h,
and further pretreated with either a p38 kinase inhibitor
(SB203580, 10 mM) or an NF-kB-speciﬁc inhibitor (SN-50peptide, 50 nM) for 30 min. The cells were then stimulated
with TNF-a (50 ng/ml) for 24 h, supernatants were collected,
andMMP-13 activity was detected. Fluorescent signals were
measured (excitation, 320 nM; emission, 405 nM) by a 1420
multilabel counter (VICTOR3; Wallac, Turku).NF-kB LUCIFERASE ASSAYNF-kB activity was directly determined by a reporter gene
assay. HTB-94 cells were transiently co-transfected with
pNF-kB-Luc (Stratagene, La Jolla, CA) and a Renilla lucifer-
ase control vector (Promega), using the Lipofectamine 2000
reagent (Invitrogen). The transfected cells were cultured in
complete medium for 24 h with or without various reagents
as indicated in each experiment, and luciferase activity
was determined with a luciferase reporter gene assay kit
(Luciferase assay system, Promega). Brieﬂy, the cells
were washed with PBS and lysed with lysis buffer. The cell
lysates were mixed with the provided luciferase assay sub-
strate, and ﬁreﬂy luminescence was measured using a VIC-
TOR3 1420 multilabel counter (Wallac). Relative luciferase
(RUL) activity was calculated as the ratio of ﬁreﬂy luciferase
activity vs Renilla luciferase activity.ResultsTHE MC1R, a-MSH RECEPTOR, IS EXPRESSED
ON HTB-94 CELLSTo validate our experimental system, we ﬁrst examined
the expression of the four a-MSH receptors (MC1R and
MC3e5R) in HTB-94 cells. The expression of MC2R was
not examined in our system because MC2R is not respon-
sive to a-MSH36. RT-PCR revealed that HTB-94 cells ex-
pressed MC1R, but did not express the other tested
receptors signiﬁcantly [Fig. 1(A)]. Western blot analysis re-
vealed that TNF-a treatment did not alter MC1R expression
[Fig. 1(B)]. The surface expression of MC1R and its non-
responsiveness to TNF-a was conﬁrmed by ﬂuorescence
microscopy in control and TNF-a-treated HTB-94 cells
labeled with goat anti-MC1R and FITC-conjugated anti-
goat antibodies [Fig. 1(C)]. The expression of MC1R was
compared between undamaged region of OA cartilage
and OA-affected damaged region in human OA cartilage
obtained from patients undergoing total knee arthroplasty.
MC1R was detected in undamaged region of OA cartilage
and its expression was signiﬁcantly increased in OA carti-
lage, whereas type II collagen expression was decreased
in OA-affected damaged region of cartilage [Fig. 1(D)].
These results suggest that MC1R is available on the surface
of HTB-94 cells and human primary chondrocytes (PHCs)
to act as the receptor of a-MSH.a-MSH INHIBITS TNF-a-INDUCED MMP-13
EXPRESSION IN HTB-94 CELLSTNF-a is known to upregulate MMP expressions in
PHCs20.Although thechondrosarcomacell line isasubstitute
for primary chondrocytes, the level of MMP-13 expression of
PHCs was similar with that of human chondrosarcoma cell
line, HTB-9427. Thus, to validate and reﬁne our experimental
system, we ﬁrst tested the effect of TNF-a on MMP expres-
sion in HTB-94 cells. Consistent with a previous report in
human chondrocytes20, our results revealed that MMP-1,
MMP-3, MMP-8, MMP-9 and MMP-13 expression levels
were increased in HTB-94 cells treated with TNF-a (50 ng/
ml) for 24 h [Fig. 2(A)]. To examine the effect of a-MSH on
Fig. 1. MC1R, an a-MSH receptor, is expressed in human chondrosarcoma HTB-94 cells and OA cartilage. Total RNA was isolated from HTB-
94 cells, and the mRNA transcript levels of various MCRs (MC1R, 495 bp; MC3R, 407 bp; MC4R, 551 bp; MC5R, 487 bp) were determined by
RT-PCR (A). HTB-94 cells were stimulated with various concentrations of TNF-a for 30 min and MC1R protein expression levels were deter-
mined by Western blot analysis (B). Cells were stimulated with TNF-a (50 ng/ml) for 30 min and then immunostained with antibody against
MC1R, followed by an FITC-labeled secondary antibody. MC1R expression was visualized by differential interference contrast (DIC, upper
panel) and ﬂuorescence microscopy (lower panel) (200) (C). Human OA cartilage was obtained from 64-year-old female patient undergoing
arthroplasty for the OA knee joints. Undamaged part of OA cartilage (normal) and arthritis-affected damaged region (OA) were sampled down
to the subchondral bone. Total RNA was isolated from human OA joint cartilage, and the mRNA levels of MC1R and human type II collagen
(350 bp) were determined by RT-PCR (D). The presented data represent typical results from at least three independent experiments.
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HTB-94 cells with a-MSH for 24 h prior to stimulation with
TNF-a (50 ng/ml). Our results revealed that the expression
of MMP-13 was signiﬁcantly reduced by a-MSH pretreat-
ment. In contrast, no changes were observed in the expres-
sion levels of MMP-1, MMP-3, MMP-8 and MMP-9 following
TNF-a treatment of a-MSH-pretreated HTB-94 cells. We
then used RT-PCR and Western blot analysis to conﬁrm
the effect of TNF-a on MMP-13 expression at the mRNA
and protein levels, respectively. Our results demonstrated
that MMP-13 mRNA and protein levels were dose-
[Fig. 2(B)] and time-dependently [Fig. 2(C)] increased in
HTB-94 cells exposed to TNF-a treatment. To examine the
dose-dependent effects of a-MSH pretreatment on MMP-13
expression in HTB-94 cells stimulated with TNF-a
(50 ng/ml). a-MSH pretreatment reduced dose-dependently
mRNA and protein levels of MMP-13 expression in TNF-
a-treated HTB-94 cells [Fig. 2(D)]. We also investigated the
receptor speciﬁcity using GHRP-6, which is a non-selective
antagonist of a-MSH receptors. When HTB-94 cells were
pretreated with GHRP-6, the inhibitory effects of a-MSH on
TNF-a-induced MMP-13 expression were completely abro-
gated [Fig. 2(E)]. In particular, MMP-13 expression was
signiﬁcantly reduced in HTB-94 cells exposed to 200 nM
a-MSH for 24 h prior to TNF-a treatment. Taken together,
these results suggest that a-MSH pretreatment blocks
TNF-a-induced MMP-13 expression in HTB-94 cells.a-MSH INHIBITS TNF-a-INDUCED MMP-13 EXPRESSION BY
BLOCKING p38 KINASE ACTIVATIONBecause TNF-a is known to activate MAPKs such as p38
kinase, ERK1/2 and JNK5, we next investigated whether the
effect of a-MSH on MMP-13 expression was mediated byMAPK signaling. Western blot analysis conﬁrmed that
TNF-a treatment activated p38 kinase, ERK1/2 and JNK in
our experimental system [Fig. 3(A)]. Interestingly, our results
revealed that pretreatment with 200 nM a-MSH signiﬁcantly
reduced TNF-a-stimulated activation of p38 kinase to near-
control levels but had no such effect on the activity of ERK1/
2 or JNK [Fig. 3(B) and (C)]. Because the MAPK signaling
pathway has been reported to regulate MMP-13 gene ex-
pression19,20, we next examined the effects of MAPK inhib-
itors on TNF-a-inducedMMP-13 expression in HTB-94 cells.
We incubated cells with 10 mM of inhibitors against ERK1/2
(PD98059), p38 kinase (SB203580), and JNK (SP600125)
for 30 min prior to stimulation with TNF-a. As shown in
Fig. 3(D), TNF-a induced MMP-13 expression was signiﬁ-
cantly decreased by pretreatment with SB203580, whereas
SP600125 and PD98059 had no such effect. In addition,
pretreatment of other ERK1/2 inhibitor (U0126, 10 mM) did
not suppress TNF-a stimulated MMP-13 expression at
the protein level as well as mRNA level [Fig. 3(E)]. These re-
sults suggest that suppression of TNF-a-induced p38 kinase
activation by a-MSH is responsible for the observed a-MSH-
induced inhibition of TNF-a-induced MMP-13 expression in
HTB-94 cells.a-MSH INHIBITS TNF-a-INDUCED MMP-13 EXPRESSION
BY BLOCKING NF-kB ACTIVATIONSince NF-kB is an important mediator of TNF-a signal
transduction in chondrocytes and reportedly regulates the
transcription of MMP-1315,18, we next investigated the effect
of a-MSH on NF-kB activation and subsequent MMP-13 ex-
pression in TNF-a-treated HTB-94 cells. We incubated cells
with an NF-kB-speciﬁc inhibitor (SN-50) for 30 min prior to
stimulation with TNF-a. As expected, SN-50 pretreatment
Fig. 2. a-MSH inhibits TNF-a induced MMP-13 expression in HTB-94 cells. Cells were treated with or without a-MSH (200 nM) for 24 h and then
stimulated with TNF-a (50 ng/ml) for 24 h, and the expression level of inducedMMPs (MMP-1, 428 bp; MMP-3, 440 bp; MMP-8, 532 bp; MMP-9,
406 bp; MMP-13, 491 bp) and actin (450 bp) mRNA were determined by RT-PCR (A). Cells were stimulated with various concentrations of
TNF-a for 24 h and the mRNA and protein expression levels of MMP-13 (62 kDa) were determined by RT-PCR and Western blot analyses,
respectively (B). Cells were stimulated with 50 ng/ml of TNF-a for various time periods, and the mRNA and protein expression levels of MMP-
13 and actin were determined by RT-PCR and Western blot analyses, respectively (C). Cells were treated with various concentrations of
a-MSH for 24 h and then exposed to TNF-a (50 ng/ml) for 24 h, and the mRNA and protein expression levels of MMP-13 and actin were deter-
mined by RT-PCR and Western blot analyses, respectively (D). Cells were pretreated with a-MSH (200 nM), a-MSH antagonist GHRP-6
(200 nM) for 24 h and then exposed to TNF-a (50 ng/ml) for 24 h. ThemRNAand protein expression levels ofMMP-13 and actin were determined
by RT-PCR and Western blot analyses, respectively (E). The presented data represent typical results from at least three independent
experiments.
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MMP-13 mRNA and protein levels [Fig. 4(A)]. Because
NF-kB activation requires activation of IKKs and degrada-
tion and phosphorylation of IkB protein37, we next examined
whether a-MSH inhibits TNF-a-induced NF-kB activation
and IkB phosphorylation. TNF-a-induced phosphorylation
levels of IkB were checked in HTB-94 cells pretreated
with a-MSH and transfected with plasmids encoding dn
forms of dnIKKa and dnIKKb. Our results revealed that
TNF-a-induced IkB-a phosphorylation was decreased in
cells treated with a-MSH, as well as those expressing
dnIKKa or dnIKKb [Fig. 4(B)]. Furthermore, TNF-a-induced
MMP-13 expression was decreased to similar degrees in
HTB-94 cells pretreated with a-MSH vs those transiently ex-
pressing dnIKKa or dnIKKb [Fig. 4(B)]. We then examined
the effect of a-MSH on the phosphorylation levels of IKKa
and IKKb in TNF-a-treated HTB-94 cells, using Western
blot analysis with anti-phospho-IKKa/b antibodies. Our re-
sults revealed that phospho-IKKa and phospho-IKKb levels
were signiﬁcantly decreased in a-MSH-pretreated cells
exposed to TNF-a [Fig. 4(C)]. These results indicate that
a-MSH pretreatment inhibits TNF-a-induced MMP-13 ex-
pression via downregulation of IKKa and IKKb, which de-
creases NF-kB activation. Because Western blot analysis
of cell lysates represents only intracellular protein expres-
sion levels, we next investigated the effect of a-MSH onsecretion of active form of MMP-13 TNF-a-treated HTB-94
cells. Cells were incubated with a-MSH (200 nM) for 24 h,
and then treated with inhibitor of NF-kB (SN-50, 50 nM)
for 30 min prior to stimulation with TNF-a (50 ng/ml). The
levels of active MMP-13 in the culture supernatant were de-
tected using the Fluorokine E active MMP-13 kit (R&D
Systems). Our results revealed that the secretion levels of
active form of MMP-13 were signiﬁcantly lower in cells pre-
treated with a-MSH, and SN-50 prior to TNF-a stimulation
[Fig. 4(D)]. Consistent with the previous results, this ﬁnding
also supports the notion that a-MSH inhibits TNF-a-induced
MMP-13 expression in HTB-94 cells by downregulating the
TNF-a-induced activation of NF-kB.a-MSH INHIBITS TNF-a-INDUCED MMP-13 EXPRESSION BY
DOWNREGULATING p38 KINASE AND SUBSEQUENTLY
NF-kB ACTIVATION IN HTB-94 CELLSSince we found that a-MSH pretreatment inhibits TNF-a-
induced activation of p38 kinase and NF-kB, we next inves-
tigated whether a functional relationship exists between the
activations of p38 kinase and NF-kB in this context. In HTB-
94 cells, TNF-a treatment caused activation of NF-kB, as
demonstrated by IkB phosphorylation analysis [Fig. 4(B)],
and also by luciferase reporter gene analyses of cells
treated with a p38 kinase inhibitor (SB203580) [Fig. 5(A)].
Fig. 3. a-MSH inhibits TNF-a-induced MMP-13 expression by blocking p38 kinase activation. Cells were stimulated with various concentra-
tions of TNF-a for 30 min and the levels of phosphorylated p38 (pp38), ERK1/2 (pERK1/2) and JNK (pJNK) were determined by Western blot
analysis (A). Cells were stimulated with various concentrations of a-MSH for 24 h and then exposed to TNF-a (50 ng/ml) for 30 min, and the
levels of pp38, pERK1/2 and pJNK were determined by Western blot analysis (B). Cells were pretreated with a-MSH (200 nM) for 24 h or
inhibitors against p38 kinase (SB203580, 10 mM), ERK1/2 (PD98059, 10 mM) or JNK (SP600125, 10 mM) for 30 min, and then exposed to
TNF-a (50 ng/ml) for 30 min. The phosphorylation levels of the MAPK subtypes were determined by Western blot analysis (C). Cells were
pretreated with 10 mM of each kinase inhibitors (PD98059, SB203580 and SP600125) for 30 min and then exposed to TNF-a (50 ng/ml) for
24 h. The mRNA and protein expression levels of MMP-13 and actin were determined by RT-PCR and Western blot analyses, respectively
(D). Cells were pretreated with 10 mM of other ERK1/2 inhibitor (U0126, 10 mM) for 30 min, and then exposed to TNF-a (50 ng/ml) for 24 h. The
mRNA and protein expression levels of MMP-13 and actin were determined by RT-PCR and Western blot analyses, respectively (E). The data
represent typical results from at least three independent experiments.
120 S. W. Yoon et al.: Anti-MMP effect of a-MSHThe latter experiments revealed that SB203580 treatment
reduced NF-kB activation levels to 25e26% of the levels
seen in TNF-a-treated control levels [Fig. 5(A)], and TNF-
a-induced MMP-13 production, respectively [Fig. 5(B)]. In
contrast, inhibition of NF-kB activation by expression of
dnIKKa or dnIKKb or treatment with SN-50 peptide did not
signiﬁcantly affect p38 kinase activation [Fig. 5(C)] but did
inhibit TNF-a-induced MMP-13 production [Fig. 5(D)].
MMP-13 expression is more sensitive to a-MSH mediated
inhibition of p38 and NF-kB activation than MMP-1, MMP-
3, and MMP-9 in HTB-94 cells [Fig. 5(E)]. Taken together,
these results indicate that a-MSH inhibits MMP-13 expres-
sion by blocking TNF-a-induced p38 kinase activation and
subsequent IKK and NF-kB activation in HTB-94 cells.Discussion
a-MSH, which is known to suppress inﬂammation by in-
hibiting the expression of inﬂammatory cytokines, prevents
local inﬂammation in an animal model of arthritis4 and is
thought to possibly have anti-inﬂammatory and immuno-
modulatory actions in arthritis patients2,4. MMPs are requi-
red for the degradation of extracellular matrix components
during tissue remodeling27, and their expressions are in-
duced by activation of proinﬂammatory cytokines. MMPs
have been shown to play roles in various inﬂammatory dis-
eases such as arthritis, asthma, and inﬂammatory bowel
disease15,38,39. However, the molecular mechanism(s) un-
derlying the effect of a-MSH on MMP expression have notpreviously been studied in chondrocytes. Here, we used
the HTB-94 human chondrosarcoma cell line to investigate
whether a-MSH inhibited the expression of MMPs induced
by a representative proinﬂammatory cytokine, TNF-a. We
found that the TNF-a-induced expression of MMP-13 was
inhibited by a-MSH pretreatment. MMP-13 was selected
for further study because a-MSH pretreatment signiﬁcantly
inhibited MMP-13 expression in our system (Fig. 2), and
because MMP-13 (collagenase-3) expression is elevated
in joint disorders, where it is believed to play an important
role in cartilage destruction by cleaving type II collagen25,26.
The elucidation of the molecular mechanism(s) underlying
a-MSH-mediated inhibition of TNF-a-induced MMP-13 ex-
pression could potentially suggest new anti-arthritis thera-
peutic candidates. Because HTB-94 chondrosarcoma cells
are not primary chondrocytes, further in vivo studies may
be required to conﬁrm the anti-arthritis effect of a-MSH.
One of the major ﬁndings in the present work is that p38
kinase is amajor signalingmolecule that transduces a-MSH-
mediated anti-arthritis signal to the nucleus by inhibiting the
NF-kB activation and MMP-13 expression in HTB-94 cells.
We observed that a p38 kinase inhibitor (SB203580), but
not ERK1/2 inhibitors (PD98059 and U0126) or a JNK
inhibitor (SP600125) signiﬁcantly inhibited TNF-a-induced
MMP-13 expression in HTB-94 cells, and further found that
a-MSH inhibited TNF-a-mediated MMP-13 expression by
downregulating p38 kinase activation (Fig. 3). Inhibition of
NF-kBactivation had no effect on the activation of p38 kinase
in our system [Fig. 5(B)], whereas a-MSH pretreatment
inhibited p38 kinase activation and the subsequent
Fig. 4. a-MSH inhibits TNF-a-induced MMP-13 expression by blocking NF-kB activation. Cells were stimulated with various concentrations of
an NF-kB speciﬁc inhibitor (SN-50) for 30 min and then exposed to TNF-a (50 ng/ml) for 24 h. The mRNA and protein expression levels of
MMP-13 were determined by RT-PCR and Western blot analyses, respectively (A). Cells were pretreated with a-MSH for 24 h and then
exposed to TNF-a (50 ng/ml) for 30 min. Alternately, cells were transfected with dn forms of dnIKKa and dnIKKb and then exposed to
TNF-a (50 ng/ml) for 30 min. The expression levels of phosphorylated IkB-a (pIkB-a), MMP-13 and actin were determined by Western blot
analysis (B). Cells were pretreated with a-MSH (200 nM) for 24 h and then exposed to TNF-a (50 ng/ml) for 30 min, and the levels of phos-
phorylated IKKa/b (pIKKa/b) and actin were determined by Western blot analysis (C). Cells were pretreated with a-MSH (200 nM) for 24 h,
treated with an NF-kB inhibitor (SN-50 peptide, 50 nM) for 30 min and then exposed to TNF-a (50 ng/ml) for 24 h. Supernatants were collected
and examined for the presence of active form of MMP-13, using a ﬂuorescent assay. The results are expressed as means SE of three
independent experiments. *, P< 0.005; **, P< 0.001 vs the value obtained in the presence of TNF-a only (D).
121Osteoarthritis and Cartilage Vol. 16, No. 1activations of IKKa/b and NF-kB. As shown in Fig. 5(E),
MMP-13 expression is more sensitive to a-MSH mediated
inhibition of p38 kinase and NF-kB activation than MMP-1,
MMP-3, and MMP-9 in HTB-94-cells. We do not know the
exact mechanism of the selective transcriptional regulation
of MMP-13 by a-MSH. Recent studies demonstrated that
MMP-13 induction involved the activation of p38 kinase
and NF-kB and putative NF-kB binding site is located in
the promoter of human MMP-13 gene40,41. Because TNF-a
induced phosphorylation of c-Jun is not inhibited by a-MSH
(data not shown), a-MSH mediated inhibition of MMP-13
may not be related with AP-1 activation. NF-kB binding
sites in the promoter of MMP-13 may be regulated by differ-
ent components of NF-kB with that of other MMPs in
HTB-94 cells. Further studies are required to understand
the mechanism of a-MSH to regulate the transcription of
MMP-13.
The present results also revealed that transient expres-
sion of dnIKKa/b or treatment with an NF-kB inhibitor
(SN-50) decreased TNF-a-induced MMP-13 expression.
These ﬁndings are consistent with previous reports thatTNF-a-induced MMP-13 expression is regulated by NF-kB
activation in human chondrocytes27e29, and also agree
with studies showing that both IKKa and IKKb directly reg-
ulate IkB-a phosphorylation and NF-kB activity41,42. Thus,
although future studies will be required to elucidate the up-
stream pathway(s) and mechanism(s) underlying a-MSH-
mediated regulation of p38 kinase, the present study shows
for the ﬁrst time that a-MSH blocks TNF-a-induced MMP-13
expression by inhibiting the activation of p38 kinase, IKKa/b,
and NF-kB.
In sum, we herein investigated the molecular mecha-
nisms of a-MSH-induced inhibition of MMP-13 expression
in TNF-a-stimulated HTB-94 human chondrosarcoma cells.
Our results revealed for the ﬁrst time that a-MSH pretreat-
ment, likely transduced by MC1R binding, suppresses
MMP-13 expression in TNF-a-stimulated HTB-94 cells via
inhibition of p38 kinase and NF-kB activation. These ﬁnd-
ings suggest for the ﬁrst time that a-MSH may be an effec-
tive inhibitor of MMP-13-mediated collagen degradation,
providing new potential opportunities for the development
of anti-arthritis therapeutics.
Fig. 5. a-MSH inhibits TNF-a-induced MMP-13 expression by downregulating p38 kinase and subsequently NF-kB activation in HTB-94 cells.
Cells were transiently co-transfected with pNF-kB-Luc and Renilla luciferase reporter plasmids, treated with or without a p38 kinase inhibitor
(SB203580, 10 mM) for 30 min, and then stimulated with TNF-a (50 ng/ml) for 30 min. NF-kB activity was determined by luciferase reporter
gene assay (A) and the mRNA and protein expression levels of MMP-13 and actin were determined by RT-PCR and Western blot analyses
(B), respectively. The results of luciferase assay are expressed as meansSE of three independent experiments. *, P< 0.005 vs the value
obtained in the presence of TNF-a only. Cells were pretreated with a p38 kinase inhibitor (SB203580, 10 mM) or an NF-kB speciﬁc inhibitor
(SN-50 peptide, 50 nM) for 30 min and then exposed to TNF-a (50 ng/ml) for 30 min. Alternately, cells were transfected with dn forms of
dnIKKa or dnIKKb and then exposed to TNF-a (50 ng/ml) for 30 min. The expression level of phosphorylated p38 kinase (pp38) was deter-
mined by Western blot analysis (C) and the mRNA and protein expression levels of MMP-13 and actin were determined by RT-PCR and West-
ern blot analyses (D), respectively. Cells were pretreated with a-MSH (200 nM) for 24 h or inhibitors against p38 kinase (SB203580, 10 mM),
JNK (SP600125, 10 mM), or NF-kB (SN-50, 50 nM) for 30 min, and then exposed to TNF-a (50 ng/ml) for 24 h. The expression levels of the
MMP-1 (57 kDa), MMP-3 (54 kDa), MMP-9 (92 kDa), and MMP-13 (62 kDa) were determined by Western blot analysis (E). The data represent
a typical result from at least three independent experiments.
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